Analysis of Serum Endothelial Cell-Specific Molecule 1 (Endocan) Level in Type 2 Diabetes Mellitus With Acute ST-Segment Elevation Myocardial Infarction and its Correlation: A Pilot Study. (January 2017)

• Record Type: Journal Article
• Authors: Qiu, Chong-Rong; Fu, Qiang; Sui, Jian; Zhang, Qian; Wei, Peng; Wu, Yan; Zhu, Ke; Lu, Yi; Wan, Peng
• Is Part Of: Angiology. Volume 68:Number 1(2017)
• Page Start: 74
• Page End: 78
• Publication Date: 2017-01
• Subjects: type 2 diabetes mellitus -- endothelial cell-specific molecule 1 -- acute ST-segment elevation myocardial infarction -- diabetes complications -- biomarker -- endocan; Blood-vessels -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.13005
• DOI: 10.1177/0003319716634581
• Languages: English
• ISSNs: 0003-3197

Abstract

Endothelial cell-specific molecule 1 (ESM-1; endocan) is expressed by endothelial cells, and it can be overexpressed in diabetic patients. However, little is known concerning diabetic patients with acute ST-segment elevation myocardial infarction (STEMI). Therefore, we assessed serum ESM-1 level in patients having type 2 diabetes mellitus (T2DM) STEMI; 72 patients with DM (38 with and 34 without vascular disease) and 33 individuals as a control group were included. There was a significant difference in serum ESM-1 level between the T2DM group and the control group ( P = .03). There was also a significant difference in serum ESM-1 level between the T2DM with STEMI group and newly diagnosed T2DM group without vascular disease ( P = .01). In patients with T2DM, serum ESM-1 levels correlated positively with high-sensitivity C-reactive protein levels and the neutrophil to lymphocyte ratio ( r = .321, P = .006 and r = .320, P = .006). Our findings suggest that serum ESM-1 level may be a novel endothelial dysfunction biomarker and it may be related to vascular disease in T2DM.